Long-term remission in an aggressive Crooke cell adenoma of the pituitary, 18 months after discontinuation of treatment with temozolomide

KEY CLINICAL MESSAGE: The clinical course of our patient, who sustained remission status for at least 18 months highlights the chance of long-term hormonal and tumor remission and demonstrates the efficacy and safety of discontinuation of temozolomide therapy. Prospective studies are required in ord...

Descripción completa

Detalles Bibliográficos
Autores principales: Asimakopoulou, Athina, Tzanela, Marinela, Koletti, Ageliki, Kontogeorgos, George, Tsagarakis, Stylianos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184761/
https://www.ncbi.nlm.nih.gov/pubmed/25356225
http://dx.doi.org/10.1002/ccr3.39
_version_ 1782337909087535104
author Asimakopoulou, Athina
Tzanela, Marinela
Koletti, Ageliki
Kontogeorgos, George
Tsagarakis, Stylianos
author_facet Asimakopoulou, Athina
Tzanela, Marinela
Koletti, Ageliki
Kontogeorgos, George
Tsagarakis, Stylianos
author_sort Asimakopoulou, Athina
collection PubMed
description KEY CLINICAL MESSAGE: The clinical course of our patient, who sustained remission status for at least 18 months highlights the chance of long-term hormonal and tumor remission and demonstrates the efficacy and safety of discontinuation of temozolomide therapy. Prospective studies are required in order to define predictors of long-term remission of this promising therapeutic modality.
format Online
Article
Text
id pubmed-4184761
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-41847612014-10-29 Long-term remission in an aggressive Crooke cell adenoma of the pituitary, 18 months after discontinuation of treatment with temozolomide Asimakopoulou, Athina Tzanela, Marinela Koletti, Ageliki Kontogeorgos, George Tsagarakis, Stylianos Clin Case Rep Case Reports KEY CLINICAL MESSAGE: The clinical course of our patient, who sustained remission status for at least 18 months highlights the chance of long-term hormonal and tumor remission and demonstrates the efficacy and safety of discontinuation of temozolomide therapy. Prospective studies are required in order to define predictors of long-term remission of this promising therapeutic modality. Blackwell Publishing Ltd 2014-02 2013-12-09 /pmc/articles/PMC4184761/ /pubmed/25356225 http://dx.doi.org/10.1002/ccr3.39 Text en © 2013 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Asimakopoulou, Athina
Tzanela, Marinela
Koletti, Ageliki
Kontogeorgos, George
Tsagarakis, Stylianos
Long-term remission in an aggressive Crooke cell adenoma of the pituitary, 18 months after discontinuation of treatment with temozolomide
title Long-term remission in an aggressive Crooke cell adenoma of the pituitary, 18 months after discontinuation of treatment with temozolomide
title_full Long-term remission in an aggressive Crooke cell adenoma of the pituitary, 18 months after discontinuation of treatment with temozolomide
title_fullStr Long-term remission in an aggressive Crooke cell adenoma of the pituitary, 18 months after discontinuation of treatment with temozolomide
title_full_unstemmed Long-term remission in an aggressive Crooke cell adenoma of the pituitary, 18 months after discontinuation of treatment with temozolomide
title_short Long-term remission in an aggressive Crooke cell adenoma of the pituitary, 18 months after discontinuation of treatment with temozolomide
title_sort long-term remission in an aggressive crooke cell adenoma of the pituitary, 18 months after discontinuation of treatment with temozolomide
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184761/
https://www.ncbi.nlm.nih.gov/pubmed/25356225
http://dx.doi.org/10.1002/ccr3.39
work_keys_str_mv AT asimakopoulouathina longtermremissioninanaggressivecrookecelladenomaofthepituitary18monthsafterdiscontinuationoftreatmentwithtemozolomide
AT tzanelamarinela longtermremissioninanaggressivecrookecelladenomaofthepituitary18monthsafterdiscontinuationoftreatmentwithtemozolomide
AT kolettiageliki longtermremissioninanaggressivecrookecelladenomaofthepituitary18monthsafterdiscontinuationoftreatmentwithtemozolomide
AT kontogeorgosgeorge longtermremissioninanaggressivecrookecelladenomaofthepituitary18monthsafterdiscontinuationoftreatmentwithtemozolomide
AT tsagarakisstylianos longtermremissioninanaggressivecrookecelladenomaofthepituitary18monthsafterdiscontinuationoftreatmentwithtemozolomide

Ejemplares similares